Peter Wehrwein has been the lead editor of Managed Healthcare Executive since February 2020.
PDTs and Part B Payment to Pharmacists for COVID-19-related Services Top AMCP Legislative Agenda | AMCP 2023
Robin Roberts to AMCP: Enjoy the Journey | AMCP 2023
The co-anchor of Good Morning America spoke about her experience when she was diagnosed with myelodysplastic syndrome.
It's Not Just the P&T Committee. Payers Are Putting Value Assessment Committees, Filters on Drug Coverage Decisions | AMCP 2023
Costs have always figured into drug coverage decisions, but value assessments have become a separate and more formalized part of the process at payer organizations, said members of a panel on value frameworks at the 2023 AMCP annual meeting. The Institute for Clinical and Economic Review (ICER) came up often during the discussion.
3.5K Expected at AMCP meeting in San Antonio | AMCP 2023
A pavilion devoted to prescription digital therapeutics and an educational track devoted to biosimilars are new this year.
Challengers of the Status Quo In Physician Payment — Paying Primary Care Physicians More Than Specialists
This part of the month's cover story series features Suzanne Delbanco, Ph.D., M.P.H., executive director of the Catalyst for Payment Reform, who has the provocative suggestion of flipping physician payment so primary care physicians are paid more, not less, than specialists. “We spend so much more on specialists than we do on primary care. While a specialist can help people who are already ill, primary care doctors can help people from becoming ill,” she says.
A New Treatment in a New Package for Cutaneous Lupus Erythematosus
Findings from a mouse model suggest that encapsulating anandamide, an endocannabinoid, could be a way to make it an effective treatment for cutaneous lupus erythematosus (CLE).
TikTok ‘Skinfluencers’ Study Shows Bloggers Far Outpace Dermatologists
The researchers say their findings argue for dermatologists embracing TikTok and promoting more high-quality content on it and other social media platforms.
Monica Li, M.D., Discusses Advances in Microneedling Techniques at AAD Annual Meeting
Monica Li, M.D., clinical instructor in Department of Dermatology and Skin Science at University of British Columbia, led a session on advances in microneedling today at the annual meeting of the American Academy of Dermatology in New Orleans.
Challengers of the Status Quo in Clinical Trials — Faster, More Accurate Studies Using a Decentralized Approach
This part of the month's cover story series features Ivan Jarry, CEO of Obviohealth. According to Jarry, companies like his that run decentralized clinical trials can solve many of the problems that bedevil clinical trials, making them cheaper, faster and more inclusive and their results more reliable. This months cover story shines a light on the companies, trends and ideas that are shaking things up and reshaping the contour of how healthcare is paid for and delivered.
Diabetes and Digital Health Interventions: They Look To Be a Match
Diabetes management may lend itself to digital health interventions for a whole set reasons. DarioHealth reported good results recently, and a meta-analysis published in Lancet Digital Health this month showed that smartphone applications and SMS-based interventions are associated with effective management of type 2 diabetes in adults.
Lilly Slashed Its Insulin Prices. Will Sanofi and Novo Nordisk Do the Same?
Patient groups and lawmakers such as Sen. Bernie Sanders want Sanofi and Novo Nordisk to follow Eli Lilly's example and reduce the prices of their insulin products. Both companies said they already have programs that bring down the cost.
Arkansas Health Officials Report That Vaccine Clinics at Meatpacking Plants Were Successful
Program reached the Marshallese workers who have moved from the island nation in the central Pacific Ocean to work in the poultry and meatpacking industry in northwest Arkansas.
FDA Approves Altuviiio, Weekly Factor VIII Therapy for Hemophilia A
The new factor VIII product is part of a surge of research and drug development for hemophilia.
CMS Sticks to Sharply Limited Coverage of New Alzheimer’s Drug, Leqembi
As with the controversial drug Aduhelm, coverage is limited to people enrolled in clinical trials. The Alzheimer’s Association had petitioned for a change.
Rituximab Gets Nod in ICER MS Report — and It's Not FDA-Approved for MS
Rituximab is cheaper and just as effective as the other monoclonal antibodies used to treat MS, says an ICER report that came out today.
Case Report Highlights Possible Paxlovid Interaction With Statins
A 72-year-old man developed worsening myalgia while taking Paxlovid. The FDA and authors of a case report in JAMA Internal Medicine today says patients who would benefit from Paxlovid should be advised to temporarily stop taking statins and other drugs with potentially serious drug-drug interactions with Paxlovid.
Medicare Coverage of Prescription Digital Therapeutics Is Top Priority for Industry Trade Group
Leaders of the Digital Therapeutics Alliance hope to get a Congressional Budget Office score on the legislation that would extend Medicare coverage so members of Congress can weigh budget implications.
PBMs Get Heavy Dose of Criticism at Senate Hearing
Senators and witnesses said at a Commerce Committee hearing today that pharmacy benefit managers are putting independent pharmacies out of business and siphoning money from the drug supply chain. A University of Chicago economist and the industry trade association pushed backed, saying they bargain to save payers and patients money.
ICER Gives NASH Drug Resmetirom High Marks, Obeticholic Acid Not So Much
At a placeholder price of $19,000, resmetirom would produce cost savings, says the drug evaluation group. Obeticholic acid’s price would need to be slashed to meet a commonly used cost-effectiveness threshold.
Mark Cuban Assails PBMs at AAM meeting
Cuban, of "Shark Tank' fame and owner of the Dallas Mavericks, called drugs prices ‘insane’ and used some profanity when talking pharmacy benefit managers at the annual meeting of the Association for Accessible Medicines yesterday. Cuban has co-founded an online pharmacy that he says will make drug prices lower and transparent.
What’s on the Mind of Margaret “Meg” Murray of the Association for Community Affiliated Plans?
Our guest on this month’s episode of the “What's on Your Mind” podcast is Margaret Murray, M.P.A., founding CEO of the Association for Community Affiliated Plans (ACAP) and a longtime member of Managed Healthcare Executive® editorial advisory board. Murray is an expert on Medicaid and healthcare policies that affect people with low incomes. In the interview with Managing Editor of MHE, Peter Wehrwein, she discusses ACAP’s growth and its legislative wins, Medicaid redetermination, “junk insurance,” and state Medicaid programs carving out pharmacy benefits.
CVS Health, Looking To Up Its Value-based Care Game, Puts Oak Street Health in Its Shopping Cart
The announcement of the $10.6 billion acquisition comes a few months after the company announced it was buying Signify Health, a home health provider, for $8 billion.
For Decades They Went Up and Up. Why Are Liver Cancer Cases and Deaths Now Leveling Off and Possibly Declining?
Testing and effective treatment of hepatitis C with the direct-acting antivirals is the most explanation.
Esophageal Cancer Update
Gastroesophageal reflux disease is a risk factor for what is now the more common type of esophageal cancer, adenocarcinoma. Immunotherapy is coming on strong as a treatment.
Rick Bates of RxSense Talks Collab With Mark Cuban's Cost Plus Drugs, Direct-To-Consumer Business and More
In this month’s episode of Tuning In to the C-Suite, Managing Editor Peter Wehrwein talks with Rick Bates, MBA, president and CEO of RxSense. In his conversation with Wehrwein, Bates described RxSense as a “technology platform company that has expertise in the direct-to-consumer business.” He emphasized that RxSense is not a pharmacy benefit manager (PBM) — but, rather, a company that supplies PBMs with technology, including some of the up-and-coming PBMs, such as EmsanaRx and Vivid Clear Rx. Bates and Wehrwein also discussed the Mark Cuban Cost Plus Drug and RxSense launching a standalone business intelligence product called Rx IQ.
After a Slow 2022, Healthcare M&A Poised To Pick Up in 2023, Says Bain
Larger payers have plenty of cash on hand to do deals but will look for “adjacencies” rather than merger and acquisition with other payers because of the regulatory environment, say Bain experts.
Amgen Launches Amjevita, First Humira Biosimilar on the U.S. Market
Amgen says it will sell the first biosimilar to Humira on the U.S. market at two prices.
Insurers Prepare to Fight RADV Rule
The Risk Adjustment Data Validation (RADV) rule was finalized today. The new rule for governing how CMS audits Medicare Advantage plans for overpayment due to inflated risk adjustment could cost insurers billions of dollars.
2 Clarke Drive Cranbury, NJ 08512